FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization for biologics, vaccines and advanced therapies, will be showcasing its viral vector platform for adeno-associated viral (AAV) vectors during the BioProcess International and Cell & Gene Therapy Manufacturing & Commercialization conferences, part of Biotech Week Boston, taking place September 27 – 30.

Additionally, we will be highlighting our local capabilities in Watertown, MA, USA, as well as the capabilities in Darlington, UK, focused on early-stage process development and cGMP manufacture. Our global, highly integrated gene therapy network also provides drug product services and commercial-scale manufacturing for gene therapy products and viral vaccines at its facility in College Station, TX, USA.

To learn more about FUJIFILM Diosynth Biotechnologies’ capabilities, schedule a meeting via ConnectMe, the event partnering app, or visit the team at Booth 219 at the Boston Convention and Exhibition Center.

Join our experts speaking at the following sessions:

  • On September 28th at 11:30 am Ian Goodwin, Director, Program Design, Advanced Therapies, will present “Strategies to Propel Your Viral Vector Therapy from Lab to Clinic”.
  • On September 29th at 11:15 am Josh Souther, Senior Scientist, will deliver the presentation on “Single-Use Recovery: Centrifugation and Depth Filtration”.

For more information, please visit the event section at fujifilmdiosynth.com

Viral vector platform: from gene to market

Our viral vector platform approach offers streamlined development leveraging triple transfection technology and ‘ready-to-go’ critical materials that can circumvent time, cost, and raw material access constraints reducing the timeline from gene to clinic and enabling rapid first-in-human clinical trials. For more information on our services within the advanced therapies, please visit our offerings site.

We welcome prospective clients and industry consultants to schedule a meeting and tour of our facilities via our company website.

About FUJIFILM Diosynth Biotechnologies
FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization with experience in the development and manufacture of biologics, vaccines, and advanced therapies. The company operates a global network with major locations in the United States of America, the United Kingdom and Denmark and it is building a new manufacturing site in Holly Springs, North Carolina, USA.

For more information, please visit fujifilmdiosynth.com or follow us on LinkedIn and Twitter.